CG Oncology, Inc. - Common stock (NQ:CGON)

69.15 -2.04 (-2.87%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist

Price and Volume

Volume	626,074
Open	71.29
Bid (Size)	54.00 (2,000)
Ask (Size)	70.20 (400)
Prev. Close	71.19
Today's Range	68.08 - 71.29
52wk Range	23.65 - 77.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

July 27, 2026

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder...

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead ↗

June 10, 2026

CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global...

Via MarketBeat

Performance

YTD	+65.5%	+65.5%
1 Month	-0.2%	-0.2%
3 Month	+2.1%	+2.1%
6 Month	+27.3%	+27.3%
1 Year	+165.0%	+165.0%

More News

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push ↗

June 07, 2026

Via MarketBeat

CG Oncology Inc (NASDAQ:CGON) Shows Perfect Technical Rating and Strong Setup Quality for Potential Breakout ↗

May 11, 2026

Via Chartmill

CG Oncology to Present at Upcoming Investor Conferences in June

May 28, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗

May 20, 2026

Via MarketBeat

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

May 19, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

May 15, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears ↗

May 15, 2026

Via MarketBeat

CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

May 11, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings ↗

May 11, 2026

Via Benzinga

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

May 08, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology to Present at Upcoming Investor Conferences in May

May 05, 2026

From CG Oncology Inc.

Via GlobeNewswire

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

Via The Motley Fool

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

Via MarketMinute

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

February 27, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

Via The Motley Fool

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Via MarketMinute

What's going on in today's session ↗

January 09, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Friday's session. ↗

January 09, 2026

Via Chartmill

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

January 09, 2026

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From CG Oncology Inc.

Via GlobeNewswire

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

Via The Motley Fool

Frequently Asked Questions

Is CG Oncology, Inc. - Common stock publicly traded?

Yes, CG Oncology, Inc. - Common stock is publicly traded.

What exchange does CG Oncology, Inc. - Common stock trade on?

CG Oncology, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for CG Oncology, Inc. - Common stock?

The ticker symbol for CG Oncology, Inc. - Common stock is CGON on the Nasdaq Stock Market

What is the current price of CG Oncology, Inc. - Common stock?

The current price of CG Oncology, Inc. - Common stock is 69.15

When was CG Oncology, Inc. - Common stock last traded?

The last trade of CG Oncology, Inc. - Common stock was at 08/03/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.